1. Home
  2. TECX vs DIAX Comparison

TECX vs DIAX Comparison

Compare TECX & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$33.31

Market Cap

393.0M

Sector

N/A

ML Signal

HOLD

Logo Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

DIAX

Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

HOLD

Current Price

$14.49

Market Cap

561.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
DIAX
Founded
2019
2005
Country
United States
United States
Employees
51
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
393.0M
561.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
DIAX
Price
$33.31
$14.49
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$80.40
N/A
AVG Volume (30 Days)
380.4K
130.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.93%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$12.42
52 Week High
$35.99
$15.85

Technical Indicators

Market Signals
Indicator
TECX
DIAX
Relative Strength Index (RSI) 67.84 24.14
Support Level $16.83 $14.49
Resistance Level $35.99 $14.97
Average True Range (ATR) 2.81 0.21
MACD 0.91 -0.08
Stochastic Oscillator 80.72 2.20

Price Performance

Historical Comparison
TECX
DIAX

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

Share on Social Networks: